Emis Share Discussion Threads

[reddave999] 21/1/2016 14:54

Could be worse i suppose ..you could hold fusionex as well.

[reddave999] 21/1/2016 12:28

i agree nurdin, they even added to there portfolio..baffling to say the least.

[nurdin] 21/1/2016 12:20

Dont understand why SCSW have been so keen on these.I must be missing something.

[hanzoo] 21/1/2016 11:04

Could you give same examples please?

[stocktrawler] 21/1/2016 10:16

A few deals deferred and everyone starts bailing out. Results are in line!

[albanyvillas] 21/1/2016 10:16

REDCHEF 21 Jan'16 - 09:08 - 219 of 223 0 0

Those jumping ship should reread the announcement. All looks positive to me. Net cash has improved despite acquisition costs and deferred NHS payments


Indeed

[aishah] 21/1/2016 09:57

Smit got a bit carried away with this one. Statements like "£15 - what's taking you so long?" a bit of a ramp imo. Today's update means it'll be a long time before £15! dyor

[nw99] 21/1/2016 09:51

Yes once that seller they mentioned has cleared we can revisit

[bpc10] 21/1/2016 09:30

SCSW pumped it up

[lomax99] 21/1/2016 09:29

Added, fall overdone.

[redchef] 21/1/2016 09:08

Those jumping ship should reread the announcement. All looks positive to me. Net cash has improved despite acquisition costs and deferred NHS payments

[wad collector] 21/1/2016 08:44

Spot the share price overreaction!
I like EMIS as a company but always felt the share price reflects future potential rather than current earnings which makes it a bit of a punt. Tempted today but then decided there are bigger bargains in the rest of the savaged market.

[stocktrawler] 21/1/2016 08:24

Bought at 9.39

[reddave999] 21/1/2016 08:23

agreed essential..

[stocktrawler] 21/1/2016 08:22

Just topped up

[essential] 21/1/2016 08:14

In this market you are smashed for not exceeding - fantastic opportunity to top up once it bottoms...

[stocktrawler] 21/1/2016 08:12

Overreaction - profits in line with strong pipeline

[albanyvillas] 21/1/2016 07:16

1800 new sites for lloyds chemists a massive contract win


Strong sales for PAS and reiinforced expectations of a strong year



Meanwhile, in Community Pharmacy we secured a contract that will grow our market share to close to 50%.

[nw99] 21/1/2016 07:11

In the final results for the year to 31 December 2015, the Group expects to report a partial impairment in goodwill related to its Secondary Care business and a write down in the carrying value of its minority investment in Pharmacy2U. These impairment charges are non-cash items and do not affect the underlying performance of the Group.

[albanyvillas] 20/1/2016 22:26

EMIS - Healthy growth - Share of the year



Effective communications between medical professionals is critical. EMIS is a healthcare technology company, founded in 1987 by two Yorkshire GPs who shared a vision of how computerising medical data could improve care. EMIS is now the UK market leader, providing software to manage surgeries, pharmacy management systems, retinal scanning and IT services to medical enterprises.

With the government keen to use IT throughout the NHS, demand for EMIS’s products and services should be strong. Despite regular headlines concerning the squeeze on the NHS, EMIS recently reported organic sales growth of 8%.

EMIS is listed on the AIM market, valued at around £675m. It has grown profits every year since it listed in 2010, accompanied by rising dividends. Analysts forecast the dividend will rise by around 10% p.a. for the next few years, but remember dividends are variable and not guaranteed, and AIMlisted shares can be more risky than main-market companies.

For me, EMIS ticks a lot of boxes; its products serve markets which will be around for years to come. It makes high margins and generates sufficient cash to pay a good dividend without relying on debt.

Market share is extremely strong and most of its revenues are recurring. Economies can blow hot or cold, but people will still get ill and healthcare providers will be seeking efficiencies regardless, so I think EMIS could be well placed for long-term growth.




apple deal coming


Emis Group Plc Makes 50% of UK’s Medical Records Compatible With Apple Inc. (NASDAQ:AAPL)’s HealthKit

JANUARY 20, 2016 BY RUCHI GUPTA IN COMPANY, NEWS, SOFTWARE & TECHNOLOGY ·
Emis Group Plc (LON:EMIS) announced that it had already made 50% of UK’s medical records compatible with Apple Inc. (NASDAQ:AAPL)’s HealthKit. This is barely a year since the launch of the HealthKit. What this could mean is that Apple might be a valuable player between patients and their doctors. EMIS is a medical software company which makes web patient record system that is being used by more than half of general practitioners (GPs) surgeries in the UK.

Currently, around 40% of all UK’s citizens own Apple iPhone, and most of them are very likely to be running a compatible version of HealthKit. This means that a large number of citizens have the chance to share their medical data with their health practitioner. About 13,500 people in the UK have created a mobile personal health record using Patient Access and HealthKit. Ben Foster, who is the patient operations observation director, stated this. He also noted that they had made about 4.4 million views in these records but they are not certain how many of these comments were shared between the patients and their system.

Ben Foster also notes that this system is currently being used to give doctors insight into limited conditions rather than giving them the real picture of an individual health. Patients can easily submit their records e.g. blood pressure so that their GP has an idea of how their condition is. In future this system could be used by even those looking to lose weight or even to handle complex conditions such as diabetes.

[aishah] 20/1/2016 21:51

Highly rated. No room from disappointment. Awaiting update. dyor

[spong_1] 20/1/2016 15:02

Let's hope any good news in the trading update isn't swallowed up by general market woes

[rathlindri] 11/1/2016 14:15

Looking like a possibility